Metabolic Breakthrough Offers Hope for Lethal Childhood Liver Cancer

CHICAGO, IL – June 01, 2026 – In a major announcement that could fundamentally alter the course of a rare and aggressive childhood cancer, researchers today revealed a pivotal discovery that redefines our understanding of Fibrolamellar Carcinoma. Reporting at the prestigious American Society of Clinical Oncology (ASCO) meeting, a team from the Nagourney Cancer Institute and Metabolomycs detailed how they have uncovered a unique metabolic weakness in the disease, paving the way for entirely new therapeutic strategies.

The breakthrough, a result of a powerful collaboration with the FibroFighters Foundation, moves beyond the often-ineffective conventional chemotherapies and points toward a future of targeted, personalized treatments for the young patients afflicted by this devastating illness. For a disease that has long stumped oncologists, this discovery represents the most significant beacon of hope in decades.

A Stubborn Foe: The Challenge of Fibrolamellar Carcinoma

Fibrolamellar Carcinoma (FLC) is a cruel paradox of oncology. It is a rare liver cancer that strikes adolescents and young adults, typically between the ages of 15 and 25, who are otherwise in the prime of their health. Unlike many liver cancers associated with cirrhosis or viral hepatitis, FLC arises in healthy livers, making its appearance all the more baffling and tragic. With only about 600 new cases diagnosed in the United States each year, its rarity has made it incredibly difficult to study, leaving patients and their families with limited options and a grim prognosis.

Currently, the only potentially curative treatment is aggressive surgery, either to remove the cancerous part of the liver or, in some cases, to perform a full liver transplant. However, even after a successful operation, the cancer returns in a staggering number of patients—some studies place the recurrence rate as high as 71%. For those whose cancer has spread or is inoperable, the outlook is dire. FLC tumors are notoriously resistant to standard chemotherapy, with response rates hovering around a mere 25%. This chemo-resistance has created a desperate unmet need for effective systemic therapies that can control the disease and prevent its relentless return.

Cracking the Metabolic Code

The new research, published concurrently in the peer-reviewed journal Cancers, explains why these tumors have been so resistant and offers a new path forward. The California-based research team combined two cutting-edge technologies to analyze the cancer from different angles. First, they used a functional profiling platform known as Ex vivo Analysis of Programmed Cell Death (EVA/PCD). This technique, pioneered by the Nagourney Cancer Institute, takes live tumor tissue from a patient and exposes it to various drugs in the lab to see which ones are effective at killing the cancer cells before ever administering them to the patient.

When FLC tumors were tested, the results were striking: they showed profound resistance to standard chemotherapies but an unexpected, dramatic sensitivity to a class of drugs that inhibit cellular metabolism. This suggested the cancer's very energy source could be its Achilles' heel.

To investigate this further, the team partnered with Metabolomycs Inc., a biotech firm specializing in targeted mass spectrometry. This technology allows for the precise measurement of metabolic byproducts in a patient's blood, creating a detailed "metabolic signature." When they compared the blood of FLC patients to that of healthy individuals, the difference was unmistakable.

“The metabolic signatures stood out like a sore thumb compared to normal controls,” said Dr. Robert Nagourney, the senior investigator on the study. This finding confirmed that the cancer fundamentally rewires the body's metabolism to fuel its own growth.

The root of this metabolic shift appears to be the cancer's unique genetic driver: a DNA gene-rearrangement known as DNAjB1-PRKACA. This fusion gene, found specifically in FLC, creates a constantly active protein that hijacks the cell's metabolic machinery. For over a century, scientists have theorized a link between cancer and cellular energy, but as Dr. Nagourney noted, “it wasn’t until the development of quantitative mass spectrometry that we could test many of these hypotheses.”

A New Paradigm: From Chemotherapy to Targeted Therapy

This discovery marks a paradigm shift in the potential treatment of Fibrolamellar Carcinoma. Instead of using the blunt instrument of chemotherapy, which attacks all rapidly dividing cells and often fails against FLC, doctors may soon be able to use "smart drugs" that specifically target the metabolic pathways the cancer depends on to survive. By cutting off the tumor's fuel supply, these therapies could prove far more effective and significantly less toxic than traditional treatments.

The use of the EVA/PCD platform is central to this new approach. It allows for a truly personalized strategy, enabling oncologists to test which specific metabolic inhibitors are most effective against an individual patient's tumor. This "test-before-you-treat" model promises to take the guesswork out of treatment selection, providing patients with the best possible chance of a positive response from the outset. This combination of identifying a fundamental vulnerability and having a tool to exploit it on a patient-by-patient basis could change the natural history of the disease.

The Power of Patient Advocacy

This landmark research was not conducted in a vacuum. It was made possible through a powerful alliance between scientists, clinicians, and a determined patient advocacy community. A key partner in the effort was the FibroFighters Foundation, a non-profit dedicated to advancing FLC research. The foundation was founded by Tom Stockwell after he tragically lost his 22-year-old son to the disease.

Working alongside the foundation's medical director, pediatric oncologist Dr. Paul Kent, Stockwell has channeled his personal loss into a mission to spare other families the same fate. For rare diseases like FLC, which often receive less attention and funding from large pharmaceutical companies, the role of such foundations is indispensable. They provide critical seed funding, build patient communities, and connect researchers, ensuring that diseases affecting even a small number of people are not forgotten.

The project also received generous support from the Bickerstaff Family Foundation, The Vanguard Cancer Foundation, and The Rosalie and Harold Rae Brown Foundation, underscoring the collaborative spirit required to tackle medicine's toughest challenges. This convergence of cutting-edge science, clinical innovation, and passionate advocacy offers a powerful new weapon in the fight against a cancer that has taken too many young lives.